氨甲环酸在儿童创伤中的有效性与安全性:系统评价与荟萃分析
该研究为系统评价与荟萃分析,检索截至2021年2月11日的多个数据库及灰色文献,纳入14篇文章(6项单机构、8项多中心回顾性队列研究)。主要结局为儿童创伤后接受氨甲环酸的生存率;在调整损伤严重程度等患者层面变量后,氨甲环酸使用与生存率提高无显著关联(aOR 0.61,95%CI 0.30-1.22),但在作战环境创伤儿童亚组中死亡风险降低(aOR 0.31,95%CI 0.14-0.68)。接受氨甲环酸与未接受者血栓栓塞事件风险无显著差异(OR 1.15,95%CI 0.46-2.87)。作者认为氨甲环酸在儿童创伤中的效用尚不明确,支持其使用的指南可能并非基于该情境下的现有证据,亟需严谨试验评估生存率及其他有意义结局并探索最佳剂量。
要点
- 在调整损伤严重程度等患者层面变量后,儿童创伤使用氨甲环酸与生存率提高无显著关联(aOR 0.61,95%CI 0.30-1.22)。
- 作战环境创伤儿童亚组中,氨甲环酸使用与死亡风险降低相关(aOR 0.31,95%CI 0.14-0.68)。
- 接受氨甲环酸与未接受者血栓栓塞事件风险无显著差异(OR 1.15,95%CI 0.46-2.87)。
- 作者认为氨甲环酸在儿童创伤中的效用尚不明确,支持其使用的指南可能并非基于该情境下的现有证据。
- 作者认为亟需开展严谨试验评估生存率及其他有意义结局,并探索氨甲环酸最佳剂量。
适用人群与场景
- 急性创伤后接受氨甲环酸治疗的儿童(纳入14项回顾性队列研究,含6项单机构和8项多中心研究)。
- 亚组:作战环境中发生创伤的儿童。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入14篇文章(6项单机构、8项多中心回顾性队列研究),检索截至2021年2月11日,无语言限制。
- 主要结局:调整患者层面变量(如损伤严重程度)后,氨甲环酸使用与儿童创伤生存率提高无显著关联(aOR 0.61,95%CI 0.30-1.22)。
- 亚组:作战环境创伤儿童中,氨甲环酸使用与死亡风险降低相关(aOR 0.31,95%CI 0.14-0.68)。
- 安全性:接受氨甲环酸与未接受者血栓栓塞事件风险无显著差异(OR 1.15,95%CI 0.46-2.87)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入研究均为回顾性队列研究。
- 局限:作者认为氨甲环酸在儿童创伤中的效用尚不明确,支持其使用的指南可能并非基于该情境下的现有证据;亟需严谨试验评估生存率及其他有意义结局并探索最佳剂量。
对床旁实践的改变
- 作者认为氨甲环酸在儿童创伤中的效用尚不明确,支持其使用的指南可能并非基于该情境下的现有证据。
- 作者认为亟需开展严谨试验评估生存率及其他有意义结局,并探索氨甲环酸最佳剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Trauma is the leading cause of childhood death in the United States. Our goal was to determine the effectiveness of tranexamic acid (TXA) in improving survival in pediatric trauma.
METHODS: MEDLINE (OVID), Embase (OVID), Cochrane Central Register databases, CINAHL (EBSCO), Web of Science (Clarivate Analytics), and grey literature sources were searched for publications reporting survival and safety outcomes in children receiving TXA in acute trauma, with no language restrictions, published until February 11, 2021. Two independent researchers assessed studies for eligibility, bias, and quality. Data on the study setting, injury type, participants, design, interventions, TXA dosing and outcomes were extracted. The primary outcome was survival in children who received TXA following trauma. Forest plots of effect estimates were constructed for each study. Heterogeneity was assessed and data were pooled by meta-analysis using a random-effects model.
RESULTS: Fourteen articles met inclusion criteria - six single-institution and eight multicentre retrospective cohort studies. Overall, TXA use was not associated with increased survival in pediatric trauma (adjusted odds ratio [aOR]: 0.61, 95% CI: 0.30-1.22) after adjustment for patient-level variables, such as injury severity. Increased survival was documented in the subset of children experiencing trauma in combat settings (aOR for mortality: 0.31, 95% CI: 0.14-0.68). There were no differences in the odds of thromboembolic events (OR 1.15, 95% CI: 0.46-2.87) in children who received TXA versus not.
CONCLUSIONS: The utility of TXA in children with trauma is unclear. Guidelines supporting TXA use in pediatric trauma may not be based on the available evidence of its use in this context. Rigorous trials measuring survival and other meaningful outcomes and exploring optimal TXA dosing are urgently needed. Study Registration (PROSPERO): CRD42020157683.
参考来源
- Kornelsen E, Kuppermann N, Nishijima DK, et al. Effectiveness and safety of tranexamic acid in pediatric trauma: A systematic review and meta-analysis. Am J Emerg Med. 2022. PMID: 35305468. doi:10.1016/j.ajem.2022.01.069
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。